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Abstract
The treatment of multidrug-resistant tuberculosis (TB) requires the use, for long periods, of drugs liable to cause signiﬁcant side effects.
In the case of misdiagnosis of multidrug-resistant TB, the patient is exposed to toxic substances without any beneﬁt. In low-income
countries, where the microbiological diagnosis of TB relies on microscopy only, the misdiagnosis of multidrug-resistant TB is very
frequent in patients persistently smear-positive despite anti-TB treatment, with the possibility of an infection due to non-tuberculous
mycobacteria (NTM) being neglected. The isolation of a mycobacterium from the sputum of a Somali patient apparently conﬁrmed the
previous diagnosis of cavitary pulmonary disease. Preliminary investigations led, at ﬁrst, to the strain being identiﬁed as multidrug-
resistant Mycobacterium tuberculosis, with ﬁndings fully in agreement with the patient’s history, which was characterized by repeated
interruptions of anti-TB treatment. Thorough phenotypic and genotypic analyses led subsequently to the recognition that the strain was
a previously unreported non-tuberculous mycobacterium. The patient, who was unresponsive to the anti-TB treatment, dramatically
improved once a drug combination active against NTM was used. A major objective of this article is to alert the medical community to
the risk, present also in settings in which sophisticated diagnostic techniques are used, that a cavitary infection due to NTM, and conse-
quently not responding to the anti-TB standard regimen, will be mistaken for multidrug-resistant TB.
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Introduction
A belief that is still held by infectious diseases physicians and
microbiologists is that the incidence of non-tuberculous
mycobacteria (NTM) is increasing in countries with low
tuberculosis (TB) endemicity, whereas it is close to zero in
developing countries characterized by a high TB burden. It is
much more likely that the increased isolation of NTM in the
developed world is a consequence of the advanced diagnostic
technologies that can be afforded, and the apparent absence
of NTM in developing countries is imputable to the very lim-
ited use of culture for diagnosis in the large majority of such
settings [1]. The legitimacy of the latter hypothesis is con-
ﬁrmed by a number of studies reporting the isolation of
NTM in Africa once sensitive cultural methods had been
adopted [2–5].
We report here the case of a African patient who was
repeatedly, and unsuccessfully, treated for pulmonary TB,
and who rapidly improved once the non-tuberculous aetiol-
ogy was acknowledged and suitable therapy was introduced.
Case report
A 62-year-old Somali man was admitted to the Infectious
Diseases Unit because of a long-standing history of low-grade
fever, weakness, weight loss, dyspnoea and productive cough.
He had joined his son and his daughter in Italy 2 months pre-
viously. His medical history included malaria, approximately
40 years before, and pulmonary TB. The diagnosis of TB had
been made in Somalia, when the patient was 58 years of age;
he carried no medical records, but reported that he had
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been given chemotherapy. Although he was unable to pro-
vide details about the drugs he had been taking, he reported
at least ﬁve interruptions to the therapy because of the war
in progress in his country.
Computed tomography showed extensive bilateral lesions,
consistent with the diagnosis of pulmonary TB. This diagno-
sis, apparently supported by sputum smears strongly positive
for acid-fast bacilli and by the ﬁrst culture data, led to stan-
dard treatment with isoniazid, rifampicin, pyrazinamide and
ethambutol. After 4 weeks of such treatment, which was
well tolerated, the results of the susceptibility testing
(Table 1) led to discontinuation of rifampicin, isoniazid and
pyrazinamide (the susceptibility test result for the last of
these was not yet available) and the addition of amikacin,
ethionamide, moxiﬂoxacin and linezolid to ethambutol [6].
The general condition of the patient rapidly improved and,
again, the treatment was well tolerated. Three weeks later,
the sputum smears became negative and the patient was dis-
charged. Following the ﬁnal recognition of the strain as a
non-tuberculous mycobacterium, clarithromycin (shown, in
the meantime, to be effective in vitro) was substituted for lin-
ezolid because of the high risk of toxicity associated with
prolonged treatment with the latter drug. Two months later,
amikacin was discontinued. The patient is now receiving clini-
cal follow-up, and his biochemical and microbiological param-
eters are being checked regularly; continuation of the
treatment is planned for at least 12 months.
Radiology
The chest computed tomography scan showed marked
retraction of the right lung, with deviation of the mediastinum
and consolidation of the right pulmonary lobes. These
showed lesions characteristic of tuberculous infection, with
multiple cavitations in a breadcrumb-like pattern, and a large
cavity, communicating with the bronchial tree, clearly
visible in the upper lobe (Fig. 1). In the upper left lobe,
parenchymal inﬁltrates with aerial bronchogram were
present, and opacities in a ‘tree in bud’ pattern [7] affected
the lingula (Fig. 2).
TABLE 1. Susceptibility testing pattern of FI-09026 obtained
using the proportion method in liquid MGIT medium and
the broth microdilution for the determination of the MICs
Drugs
Proportion
method
MIC (mg/L)
(interpretation)
Amikacin S 8 (S)
Ciproﬂoxacin 2 (I)
Clarithromycin 0.5 (S)
Ethambutol S 4 (I)
Gatiﬂoxacin 0.5 (S)
Linezolid S 0.5 (S)
Minocycline 4 (I)
Moxiﬂoxacin S 0.5 (S)
Rifabutin R 0.25 (S)
Rifampicin R 4 (I)
Streptomycin R >64 (R)
Trimethoprim–sulphamethoxazole 4–76 (R)
Capreomycin S
Ethionamide S
Isoniazid R
Kanamycin R
Pyrazinamide S
FIG. 1. Computed tomography scan showing, in the right lung, a
large cavity communicating with the bronchial tree and tuberculous
inﬂammation of the lobes with multiple cavitation.
FIG. 2. Computed tomography scan showing, in the lingula (right
lung), opacities in a ‘tree in bud’ pattern.
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Microbiology
Microbiological investigations were initially characterized by
contradictory results. Acid-fast microscopy (auramine–rhoda-
mine stain) revealed a heavy load of elongated and curved
bacilli, in morphology fully compatible withMycobacterium tuber-
culosis. Real-time PCR (COBAS TaqMan; Roche Diagnostics,
Basel, Switzerland) for M. tuberculosis complex (MTBC), per-
formed directly on the sputum, gave a negative result. Various
cultures in liquid medium (MGIT; Becton Dickinson, Towson,
MD, USA) [8] grew acid-fast bacilli in 5–9 days, and showed the
corded arrangement typical of M. tuberculosis. On Lowenstein–
Jensen medium, non-pigmented rough colonies, indistinguish-
able from M. tuberculosis, grew in approximately 20 days.
The identiﬁcation of the strain (FI-09026) as belonging to the
MTBC was apparently conﬁrmed by the reverse hybridization
line probe assay GenoType Mycobacterium CM (Hain Life-
science, Nehren, Germany) [9] targeting the 23S rDNA. The
use of a further reverse hybridization test, GenoType MTBC
(Hain Lifescience) [10], suitable for differentiating the species
included in the MTBC, however, produced further confusion.
Again, a positive result was obtained with theMTBC-speciﬁc line
probe, but none of the nine gyrB stretches harbouring polymor-
phisms characterizing single MTBC species could be ampliﬁed.
Genetic investigation of mutations responsible for rifampi-
cin and isoniazid resistance, performed using GenoType
MTBDRplus (Hain Lifescience) [11], to verify the suspicion of
multidrug-resistant TB, was not able to detect any, either
mutant or wild type, of the speciﬁc targets (rpoB, inhA and
katG). The test conﬁrmed, however, the presence of a
sequence of 23S rRNA speciﬁc for the MTBC.
Antimicrobial susceptibility testing was at ﬁrst performed
according to the proportion method (validated for M. tuber-
culosis strains only) in MGIT medium, using a wide panel of
ﬁrst-line and second-line drugs [12]. It revealed a pattern
(Table 1) suggestive of multidrug-resistant TB.
When the MICs were determined using the microdilution
method recommended by the CLSI for NTM [13], most of
the second-line drugs, among them linezolid and amikacin,
were shown to be effective (Table 1).
HPLC of cell wall mycolic acids, undertaken to try to
resolve these identiﬁcation uncertainties, revealed a pattern
characterized by a single, late cluster of peaks, which differed
from those obtained with M. tuberculosis [14] in the relative
heights of several peaks (Fig. 3).
Despite the multiple indications that the strain belonged
to the MTBC, several ﬁndings did not seem to support such
a hypothesis. A genetic sequencing approach was therefore
attempted to try to resolve the problem.
Double-strand sequencing was implemented using BigDye
Terminator chemistry and an AB3730 DNA sequencer
(Applied Biosystems, Foster City, CA, USA) on four genetic
species markers of primary importance for the taxonomic
and phylogenetic analysis of mycobacteria. In addition to the
16S rDNA gene, universally considered to be the ﬁrst choice
[15], the hypervariable region of the gene encoding for the
65-kDa heat shock protein (hsp65) [16] and the internal
transcribed spacer (ITS) interposed between the 16S and the
23S rDNAs [17] were sequenced. A recently proposed frag-
ment of the rpoB gene [18] was also investigated.
All of the sequences above turned out to be unique
and more closely related to the recently described species
Mycobacterium riyadhense [19]. In the almost complete
sequence of the 16S rDNA of the current isolate,
FI-09026 (GenBank accession number FJ786255), the simi-
larity to the latter species was 99%, with nine mismatches
in 1438 bp. In the hypervariable region of hsp65 [20]
(accession number FJ786253), there were 13 mismatches
(in 423 bp; similarity 96%). In the ITS (accession number
FJ786255), the presence of 13 mismatches in 278 bp was
responsible for a similarity of 95%. In the 744-bp stretch
of rpoB (FJ786254), M. riyadhense did not appear, at ﬁrst,
to be the closest species; however, once we realized that,
for the latter species, this genetic region was not yet
present in GenBank and we had determined such a
sequence in the type strain (accession number FJ786256),
M. riyadhense again turned out to present the closest sim-
ilarity (95%, with 37 mismatches). In the same regions, the
FIG. 3. Representative HPLC pattern of FI-09026 in comparison
with that of Mycobacterium tuberculosis (IS, internal standard).
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similarities with M. tuberculosis were clearly lower: 98% in the
16S rDNA, 86% in hsp65, 88% in the ITS, and 91% in rpoB.
Surprisingly, in the ﬁrst part of the 23S rDNA (accession
number FJ786255), which is known to include the target on
which the GenoType identiﬁcation probes rely, the similarity
of FI-09066 to M. tuberculosis was also low (<97%).
The phylogenetic analysis conducted using the neighbour-
joining algorithm (MEGA 4 software) [21] on the 1730-bp
sequence, including the 16S rDNA and ITS, demonstrated
the relatedness of FI-09026 and M. riyadhense (with the two
strains belonging, however, to clearly distinct branches) and
the sharp divergence from M. tuberculosis (Fig. 4).
Discussion
This is the second report of a mycobacterial strain, phenotypi-
cally mimicking M. tuberculosis but nevertheless clearly distinct
from it, being responsible for severe disease that is indistin-
guishable from TB. The ﬁrst case concerned a 19-year-old
male with painful swelling of the left side of his face due to a
tumour in the maxillary sinus extending into the nasal septum
and the left orbit. Because of the isolation of a mycobacterium
from lavage of maxillary sinuses, the patient was treated with a
9-month anti-TB regimen, which produced a clear improve-
ment. A thorough characterization of the strain revealed it to
be a non-tuberculous mycobacterium, and led to the descrip-
tion of the new species M. riyadhense [19].
Major features shared by FI-09026 and M. riyadhense
include the bacillary morphology, the colony appearance, the
misidentiﬁcation as M. tuberculosis by GenoType CM, and
the unquestionable pathogenicity. They differ, however, in
antimicrobial susceptibility, both in vitro and in vivo: the infec-
tion due to M. riyadhense was successfully treated with stan-
dard anti-TB therapy that was ineffective against FI-09026.
The similarity of FI-09026 to M. tuberculosis is striking. Micro-
scopically, FI-09026 is characterized by lengthened and curved
bacillary morphology, similarly toM. tuberculosis. Likewise, colo-
nies grown on solid media are rough and non-pigmented, simi-
lar to colonies of M. tuberculosis, and require comparable
incubation periods to become visible to the naked eye. The
arrangement of bacilli in liquid MGIT medium is characterized
by the cord morphology that is considered to be a distinctive
feature ofM. tuberculosis [22]. The pattern of results of the main
biochemical tests used for species identiﬁcations is very close
(data not shown), with only the niacin result being discrepant:
consistently positive in M. tuberculosis (but not in other species
of the MTBC) and negative in FI-09026. The HPLC proﬁle of
cell wall mycolic acids did not allow unquestionable differentia-
tion. The antimicrobial susceptibility is clearly different from
that of M. tuberculosis but, paradoxically, the resistance of FI-
09026 to the ﬁrst-line anti-TB drugs, instead of suggesting a
possible non-tuberculous mycobacterium, brought to mind a
multidrug-resistant M. tuberculosis strain. The hybridization pat-
tern obtained using the popular molecular identiﬁcation system
GenoType CM does not distinguish FI-09026 from the MTBC.
As a consequence of the above-mentioned features, the
probability of misdiagnosis of multidrug-resistant TB is very
high. This is true for low-income countries, in which the diag-
nosis of TB relies on smear microscopy only [23], but is equally
true for a high proportion of laboratories in the developed
world, including practically all those that base the identiﬁcation
of mycobacteria on methods other than genetic sequencing.
At present, we can only speculate about the real distribu-
tion of strains with the features of FI-09026. They may,
indeed, not be very rare, and the major objective of this arti-
cle is to alert the medical community to the possibility that
some isolates considered to be multidrug-resistant M. tuber-
culosis may not actually be so.
Although we are unwilling to describe a new species until
additional strains are detected, we propose, for the strain
characterized here, the name ‘Mycobacterium simulans’ (simu-
lans meaning ‘imitative’). The strain has been deposed in the
German Collection of Microorganisms and Cell Cultures
with the accession number DSM45395.
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FIG. 4. Phylogenetic tree of selected Mycobacterium species based
on sequences (1730 bp) of the ribosomal operon. The scale bar rep-
resents a 0.2% difference in nucleotide sequences. Bootstrap values
are indicated at the nodes. FJ786255 is the accession number of the
current strain (FI-09024).
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